News tagged with erlotinib
Tumors with ALK rearrangements can harbor more mutations
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Gene signature can predict who will survive chemotherapy
An eight gene 'signature' can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central's open access journal BMC Medicine.
Cancer
Apr 15, 2013 |
not rated yet |
0
New treatment holds promise for resistant lung cancer
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...
Cancer
Apr 09, 2013 |
not rated yet |
0
A hijacking of healthy cellular circuits
Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor (EGFR), ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Comparing combination therapies for advanced head and neck cancer shows no improvement
Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50 percent ...
Cancer
Mar 07, 2013 |
1 / 5 (1) |
0
New drug combination could prevent head and neck cancer in high-risk patients
(Medical Xpress)—A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included ...
Cancer
Feb 19, 2013 |
not rated yet |
0
Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'
The central skill of cancer is its ability to mutate – that's how it became cancerous in the first place. Once it's started down that path, it's not so difficult for a cancer cell to mutate again and again. This means that ...
Cancer
Dec 01, 2012 |
5 / 5 (1) |
0
Study shows different approach after progression in non-small cell lung cancer patients
Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib ...
Cancer
Nov 15, 2012 |
not rated yet |
0
Painless skin rash predicts survival benefit from latest lung cancer drug, study finds
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, c ...
Cancer
Oct 17, 2012 |
not rated yet |
0
Study says VeriStrat predicts response but not survival benefit from erlotinib
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefi ...
Cancer
Oct 15, 2012 |
not rated yet |
0
Scientists reverse Alzheimer's-like memory loss in animal models by blocking EGFR signaling
A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness ...
Alzheimer's disease & dementia
Sep 24, 2012 |
4.8 / 5 (4) |
0
|
Scientists looking for second-line defense for patients with NSCLC
DENVER- In lung cancer, patients who benefit from drugs like erlotinib will inevitably develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists are investigating a second ...
Cancer
Jul 25, 2012 |
not rated yet |
0
Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable
The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to results of a phase I study ...
Cancer
Jun 19, 2012 |
not rated yet |
0
The right combination: Overcoming drug resistance in cancer
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed ...
Cancer
Jun 01, 2012 |
not rated yet |
0
New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd ...
Cancer
Apr 18, 2012 |
5 / 5 (1) |
0
Erlotinib
Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.
For more information about Erlotinib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
